Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ab4ac1100001965b792310f0d20666c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd8d3eb1dce92c89e89ac51b5b0fc5aa |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 |
filingDate |
2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd7f54ecca4bd736dcd521f0a71e9967 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dc14a1329f0b3226cdf57edc59f863f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42a20058d0a83d1700aeb0acdce8a21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7662cb3d65b5932e42e9ee3a1e2c0607 |
publicationDate |
2021-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20210109812-A |
titleOfInvention |
Nano-complex for Oral Delivery of Parathyroid Hormone Agents |
abstract |
Herein, an anionic glycosaminoglycan (glycosaminoglycan) and a bile acid are covalently bonded conjugates; And it provides a nanocomposite for oral administration in which the PTH-based drug is connected by electrostatic interaction. The nanocomposite of the present invention can be used as a non-invasive and targeted formulation for oral administration to bone diseases by using a functional mechanism between bile acids and mucous membranes. Oral delivery of a PTH-based drug loaded with a conjugate can accumulate at the target site without physical degradation during the residence time in the gastrointestinal tract, be absorbed almost completely, and enter the systemic circulation. |
priorityDate |
2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |